Balanced View on RCKT: Clinical Progress Offsetting Execution and Regulatory Risks Supports Hold Rating

Rocket Pharmaceuticals (RCKT) has received a new Hold rating, initiated by TD Cowen analyst, Tara Bancroft.

Tara Bancroft has given his Hold rating due to a combination of factors tied to both clinical progress and remaining execution risk. The partial resolution of the FDA hold on the pivotal Danon study and the plan to cautiously resume dosing under a revised protocol support the long‑term opportunity, but also highlight lingering safety concerns and an extended development timeline.

At the same time, the encouraging early data and RMAT designation for RP‑A601 in PKP2‑ACM, together with upcoming milestones such as the initial dosing of the BAG3 program and the potential approval of Kresladi and related PRV monetization, offer upside optionality. However, with key value drivers still at relatively early or mid‑stage development and important regulatory and clinical design questions outstanding, Bancroft views the risk‑reward as balanced rather than compelling, supporting a neutral Hold stance on RCKT at this time.